Optec Receives First Shipment of Home Use FDA Approved Rapid Antigen Test Kits

Rhea-AI Summary

OPTEC International, Inc. (OTC Pink:OPTI) announced the receipt of its first shipment of FDA-approved Antigen Home Use Rapid Test Kits at its Vista, California distribution center. Following recent FDA relaxations of emergency use regulations, these rapid tests will be available for both consumers and businesses, providing results in just 15 minutes. The company will offer two versions of the nasal swab tests, which have demonstrated a Positive Percent Agreement of 88.37% and a Negative Percent Agreement of 100%. Kits will be available online shortly, enhancing testing accessibility amid the ongoing pandemic.

Positive

• Received FDA-approved Antigen Home Use Rapid Test Kits.
• Test results available in 15 minutes, improving accessibility.
• High reliability (PPA: 88.37%, NPA: 100%) of the test kits.
• Kits will soon be available online for consumers and businesses.

Negative

• None.

CARLSBAD, CA / ACCESSWIRE / April 8, 2021 / OPTEC International, Inc. (OTC Pink:OPTI), a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), announced the company today received the first shipment of FDA approved Antigen Home use Rapid Test Kits at the OPTEC Vista, California distribution center.

Due to a recent FDA relaxation of the "emergency use" (EUA) rules applicable for Rapid Test Kit use, most FDA/EUA approved Antigen and Antibody Test Kits will soon be available for purchase by consumers and businesses, both online and over the counter at affordable prices compared to the current Medical facility/Pop-Up medical staff supervised locations with 24-72-hour results.

OPTEC CEO Roger Pawson stated We are fortunate to have received some of the first FDA authorized 15 Minute Home Use Test kits for consumer and business rapid testing with onsite results in 15 minutes or less. We are anticipating having the kits available for order by consumers on the company's website within the next week.

OPTEC is providing 2 versions of the Nasal CoV-2 Antigen FDA EUA authorized 15-minute rapid test kits. The kits are clinically proven to be reliable and accurate (Clinical evaluation: Positive Percent Agreement (PPA): 88.37% (95% CI: 75.52% - 94.93%), Negative Percent Agreement (NPA): 100% (95% CI: 94.25% - 100%).

The Nasal swab tests detect viral shedding of the RNA of the virus. Using the Antigen Rapid Test Kits provides the ability for all necessary resources to help keep the pandemic at bay for personal family satisfaction, business employee monitoring, schools, senior care centers, medical & dental facilities, government divisions and more.

OPTEC will be offering both versions of the Antigen 10 Minute Nasal Rapid Test Kits: online, via distributors, media channels and bulk PPE networks.

About OPTEC International, Inc. With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information, visit: www.optecintl.com

OPTEC International, Inc. investor relations at: www.optecintl.com/investor

Safe Harbor Statement: Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Opti, OPTEC or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. OPTEC International Inc.

OPTEC International, Inc.

Investor Relations Contact:
Andrew Barwicki
516-662-9461 / Andrew@barwicki.com

SOURCE: Optec International, Inc.

View source version on accesswire.com:
https://www.accesswire.com/639565/Optec-Receives-First-Shipment-of-Home-Use-FDA-Approved-Rapid-Antigen-Test-Kits

FAQ

What are the benefits of OPTEC's FDA-approved Rapid Test Kits?

The Rapid Test Kits provide quick results in 15 minutes, improving testing accessibility for consumers and businesses.

When will OPTEC's Rapid Test Kits be available for purchase?

The Rapid Test Kits are expected to be available for order on OPTEC's website within the week following the press release.

What is the accuracy of OPTEC's Rapid Antigen Test Kits?

The test kits have a Positive Percent Agreement of 88.37% and a Negative Percent Agreement of 100%, demonstrating high reliability.

How does OPTEC's testing kit compare to traditional testing methods?

OPTEC's Rapid Test Kits offer fast onsite results in 15 minutes, compared to the 24-72 hours typically required for supervised tests at medical facilities.